Advisor Resource Council’s Ligand Pharmaceuticals LGND Stock Holding History

Advisor Resource Council’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$368K	Buy	1,147 +135	+13%	+$31.8K	0.1%	179
2026 Q1	$202K	Buy	+1,012	New	+$200K	0.07%	227
2025 Q2	–	Sell	-22,425	Closed	-$2.24M	–	401
2025 Q1	$2.24M	Buy	+22,425	New	+$2.54M	0.18%	140
2024 Q1	–	Sell	-2,804	Closed	-$200K	–	382
2023 Q4	$200K	Buy	+2,804	New	+$165K	0.02%	459

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisor Resource Council's LGND Position: Q2 2026 in Review

Advisor Resource Council increased its Ligand Pharmaceuticals (LGND) stake by 13% in Q2 2026, buying an estimated $31.8K and bringing the position to 1,147 shares worth $368K. The position accounts for 0.1% of the portfolio, ranked #179.

Advisor Resource Council first reported a position in LGND in Q4 2023 and has held it in 4 quarters since. The position peaked at $2.24M in Q1 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Advisor Resource Council held 1,147 shares of Ligand Pharmaceuticals worth $368K as of Q2 2026.
Advisor Resource Council bought 135 Ligand Pharmaceuticals shares in Q2 2026, an estimated $31.8K.
Ligand Pharmaceuticals made up 0.1% of Advisor Resource Council's portfolio in Q2 2026, its #179 holding.
Advisor Resource Council first reported a position in Ligand Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
Advisor Resource Council's Ligand Pharmaceuticals position peaked at $2.24M in Q1 2025.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Advisor Resource Council's 13F filing for Q2 2026, filed 28 Jul 2026.